• What is GNAQ?
  • GNAQ in Melanoma
  • GNAQ c.626A>C (Q209P)
  • Clinical Trials

GNAQ

Guanine nucleotide binding proteins (G proteins) are a family of heterotrimeric proteins which couple seven transmembrane domain receptors to intracellular cascades, including neurotransmitter, growth factor, and hormone signaling pathways (for review, see Neves, Ram, and Iyengar 2002 and Rosenbaum, Rasmussen, and Kobilka 2009). Heterotrimeric G proteins are composed of three subunits, Gα, Gß, and Gγ (Figure 1); each of the subunits has many different family members. The GNAQ gene encodes the Gq alpha subunit (Gαg). Receptor activation catalyzes the exchange of GDP (guanosine diphosphate) to GTP (guanosine triphosphate) on the Gα subunit, resulting in the dissociation of the Gα subunit from Gßγ. Both Gα and Gßγ can then activate downstream cellular signaling pathways. The signal is terminated when GTP is hydrolyzed to GDP by the intrinsic GTPase activity of the Gα subunit. Oncogenic mutations result in a loss of this intrinsic GTPase activity, resulting in a constitutively active Gα subunit (Kalinec et al. 1992; Landis et al. 1989).

heterotrimeric-g-protein.png

Figure 1.
Schematic of heterotrimeric G protein signaling. Activation of a 7 transmembrane G-protein coupled receptor results in exchange of GDP for GTP on the Gα subunit. The GTP bound form of Gα then dissociates from Gßγ. Multiple downstream cellular effector pathways can be activated by G protein signaling.

Contributors: Christine M. Lovly, M.D., Ph.D., Jeff Sosman, M.D., William Pao, M.D., Ph.D. (through April 2014)

Suggested Citation: Lovly, C., J. Sosman, W. Pao. 2014. GNAQ. My Cancer Genome http://www.mycancergenome.org/content/disease/melanoma/gnaq/?tab=0 (Updated August 20).

Last Updated: August 20, 2014

GNAQ Mutations in Melanoma

Somatic mutations in GNAQ have been found in ~50% of primary uveal melanomas and up to 28% of uveal melanoma metastases (Onken et al. 2008; Van Raamsdonk et al. 2009van Raamsdonk et al. 2010​). In all malignant melanoma, GNAQ mutations are found in about 1% of samples (COSMIC​). GNAQ mutations are rare in extraocular melanoma (Van Raamsdonk et al. 2009).

The majority of melanoma-associated mutations in GNAQ have been detected at codon 209 within exon 5 of the gene, a region within the catalytic (GTPase) domain of GNAQ. Mutation at this site inactivates the GTPase domain, resulting in a constitutively active GNAQ protein which is 'locked' in the GTP bound form (Kalinec et al. 1992; Landis et al. 1989). Expression of GNAQ Q209L in mice results in melanocyte transformation and increased signaling through the MAPK pathway (Van Raamsdonk et al. 2009).

In the vast majority of cases, GNAQ mutations are non-overlapping with other oncogenic mutations found in melanoma (e.g., BRAF mutations, KIT mutations, etc.). Currently, there are no direct anti-GNAQ therapies available.

Contributors: Christine M. Lovly, M.D., Ph.D., William Pao, M.D., Ph.D. (through April 2014), Jeff Sosman, M.D.

Suggested Citation: Lovly, C., W. Pao, J. Sosman. 2014. GNAQ Mutations in Melanoma. My Cancer Genome http://www.mycancergenome.org/content/disease/melanoma/gnaq/ (Updated August 8).

Last Updated: August 8, 2014

GNAQ c.626A>C (Q209P) Mutation in Melanoma

Properties
Location of mutation Exon 5, Codon 209 of GNAQ
Frequency of GNAQ mutations in primary uveal melanoma ~50% (Onken et al. 2008Van Raamsdonk et al. 2009van Raamsdonk et al. 2010​)​
Frequency of Q209P mutation among GNAQ mutant primary uveal melanoma ~64%
Implications for Targeted Therapeutics
Response to BRAF inhibitors Unknown at this time
Response to MEK inhibitors Unknown at this timea
Response to KIT inhibitors Unknown​ at this time

The Q209P mutation results in an amino acid substitution at position 209 in QNAQ, from a glutamine (Q) to a proline (P). This mutation occurs within the catalytic (GTPase) domain of GNAQ and results in a constitutively active QNAQ protein (Kalinec et al. 1992; Landis et al. 1989). GNAQ mutations are usually found in tumors wild type for NRAS, BRAF, KIT, and other driver mutations. Currently, there are no direct anti-GNAQ therapies available.

a Preclinical data have shown that a melanoma cell line harboring the GNAQ Q209L mutation is sensitive to the MEK inhibitor, U0126 (Van Raamsdonk et al. 2009). ​

Contributors: Christine M. Lovly, M.D., Ph.D., William Pao, M.D., Ph.D. (through April 2014), Jeff Sosman, M.D.

Suggested Citation: Lovly, C., W. Pao, J. Sosman. 2013. GNAQ c.626A>C (Q209P) Mutation in Melanoma. My Cancer Genome http://www.mycancergenome.org/content/disease/melanoma/gnaq/102/ (Updated September 9).

Last Updated: September 9, 2013

GNAQ-Associated Melanoma Clinical Trials

Great effort was made to include all clinical trials relevant for this mutation. However, the completeness of this information cannot be guaranteed.

Loading United States Trials...

Protocol Phase Title

Loading International Trials...

Protocol Phase Title

Loading Unknown Location Trials...

Protocol Phase Title

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.